Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
The company operates as a pharmaceutical company. The company researches, manufactures, and markets active pharmaceutical ingredients, intermediate chemicals, and finished dosages.
Hetero Drugs Limited, is an unlisted public company incorporated on 06 April, 1993. It is classified as a public limited company and is located in , Telangana. It's authorized share capital is INR 10.00 cr and the total paid-up capital is INR 3.45 cr.
Read more
** All rupee values in INR crores. Based on March 2024 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
State | Type | Address |
---|
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Director | Adi Sesha Giri Jagarapu | 08774486 | 4 years |
Director | Kalavathi Bandi
Shareholder
|
00194597 | 10 years |
Director | Venkatanarasa Reddy Attunuri
Shareholder
|
00023432 | 27 years |
Whole-time Director | Sambi Reddy Jonnala
Shareholder
|
00211459 | 13 years |
Director | Parthasaradhi Reddy Bandi
Shareholder
|
00015899 | 17 years |
Director | Rathnakar Reddy Kura
Shareholder
|
00211510 | 12 years |
Director | Bandi Vamsikrishna
Shareholder
|
01014619 | 17 years |
Director | Gopal Reddy Annareddy | 07306495 | 2 years |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales | 1,842.5 | 2,403.4 | 2,456.3 | 2,936.4 | 2,846.4 |
Operating profit | 260.2 | 341.8 | 241.0 | 272.6 | 265.2 |
Net profit | 187.3 | 223.4 | 99.9 | 164.9 | 89.6 |
Gross margin | 36.7 | 34.5 | 32.9 | 31.0 | 32.1 |
Operating margin | 14.1 | 14.2 | 9.8 | 9.3 | 9.3 |
Net margin | 9.9 | 9.1 | 4.0 | 5.5 | 3.1 |
Networth | 1,615.0 | 1,836.5 | 2,013.0 | 2,175.0 | 2,262.3 |
Borrowings | 351.9 | 244.5 | 392.6 | 399.4 | 590.5 |
Assets | 2,594.0 | 2,776.8 | 3,129.2 | 3,398.8 | 3,655.7 |
Debt to equity | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 |
Current ratio | 1.9 | 2.1 | 1.9 | 2.0 | 1.9 |
ROE | 11.6 | 12.2 | 5.0 | 7.6 | 4.0 |
Days payable | 131.0 | 112.0 | 122.0 | 114.0 | 112.0 |
WC days | 132.0 | 124.0 | 132.0 | 131.0 | 137.0 |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |
Reserves | 1,611.6 | 1,833.1 | 2,009.6 | 2,171.6 | 2,258.8 |
Borrowings + | 351.9 | 244.5 | 392.6 | 399.4 | 590.5 |
Long term borrowings | 64.4 | 32.4 | 4.1 | 2.9 | 13.0 |
Short term borrowings | 287.5 | 212.1 | 388.5 | 396.5 | 577.5 |
Trade payables + | 419.7 | 482.4 | 552.7 | 632.4 | 590.6 |
Days payable | 131.0 | 112.0 | 122.0 | 114.0 | 112.0 |
Other liabilities + | 627.0 | 695.8 | 723.5 | 824.4 | 802.9 |
Other non-current liabilities | 132.4 | 132.9 | 133.9 | 148.0 | 180.5 |
Other current liabilities | 74.9 | 80.4 | 37.0 | 44.0 | 31.8 |
Total liabilities | 2,594.0 | 2,776.8 | 3,129.2 | 3,398.8 | 3,655.7 |
Fixed Assets + | 606.8 | 633.1 | 686.9 | 717.4 | 824.8 |
Tangible assets | 518.2 | 551.4 | 607.7 | 627.2 | 687.1 |
CWIP | 25.0 | 22.0 | 19.8 | 27.7 | 43.0 |
Intangible assets | 63.7 | 59.7 | 59.5 | 62.5 | 94.7 |
LT loans and advances | 210.9 | 149.2 | 74.7 | 54.9 | 66.6 |
Other non-current assets | 329.7 | 401.2 | 499.9 | 497.4 | 492.8 |
Current assets + | 1,446.5 | 1,593.3 | 1,867.7 | 2,129.1 | 2,271.4 |
Inventories | 396.3 | 575.0 | 826.6 | 1,023.6 | 1,111.0 |
Trade receivables | 825.9 | 843.5 | 819.0 | 864.4 | 937.5 |
Cash and cash equivalents | 2.6 | 18.1 | 9.7 | 21.0 | 21.9 |
ST loans and advances | 114.4 | 72.9 | 45.4 | 29.4 | 29.2 |
Other current assets | 107.3 | 83.9 | 166.9 | 190.7 | 171.9 |
Total assets | 2,594.0 | 2,776.8 | 3,129.2 | 3,398.8 | 3,655.7 |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales + | 1,842.5 | 2,403.4 | 2,456.3 | 2,936.4 | 2,846.4 |
Sales growth % | 12.39 | 30.44 | 2.2 | 19.54 | -3.06 |
Expenses + | 1,662.3 | 2,143.3 | 2,292.2 | 2,766.2 | 2,702.0 |
Cost of goods | 1,165.7 | 1,574.6 | 1,648.2 | 2,027.3 | 1,931.9 |
Employee cost | 132.1 | 143.7 | 172.1 | 190.7 | 202.5 |
Other costs | 284.5 | 343.4 | 395.1 | 445.7 | 446.9 |
Operating profit + | 260.2 | 341.8 | 241.0 | 272.6 | 265.2 |
Operating margin % | 14.1 | 14.2 | 9.8 | 9.3 | 9.3 |
Other income | 50.5 | 39.8 | 52.2 | 67.7 | 26.1 |
Interest | 32.7 | 30.2 | 23.8 | 45.8 | 54.0 |
Depreciation | 47.3 | 51.4 | 53.1 | 56.6 | 66.7 |
Exceptional items | - | - | - | - | - |
Profit before tax | 230.7 | 299.9 | 216.3 | 237.9 | 170.6 |
Tax | 43.5 | 76.6 | 116.4 | 73.0 | 81.0 |
Profit - disc. ops | - | - | - | - | - |
Net profit | 187.3 | 223.4 | 99.9 | 164.9 | 89.6 |
Net margin % | 9.9 | 9.1 | 4.0 | 5.5 | 3.1 |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Solvency + | |||||
Total Debt/Equity | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 |
Net Debt/Equity | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 |
Total Debt/Assets | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
Total Assets/Equity | 1.6 | 1.5 | 1.6 | 1.6 | 1.6 |
Liquidity + | |||||
Current Ratio | 1.9 | 2.1 | 1.9 | 2.0 | 1.9 |
Quick Ratio | 1.3 | 1.3 | 1.1 | 1.0 | 1.0 |
Interest Coverage | 8.0 | 11.3 | 10.1 | 6.0 | 4.9 |
Performance | |||||
Gross Margin | 36.7 | 34.5 | 32.9 | 31.0 | 32.1 |
Operating Margin | 14.1 | 14.2 | 9.8 | 9.3 | 9.3 |
Net Margin | 9.9 | 9.1 | 4.0 | 5.5 | 3.1 |
Return + | |||||
Return on Equity | 11.6 | 12.2 | 5.0 | 7.6 | 4.0 |
Pre-tax ROCE | 16.8 | 20.0 | 11.9 | 12.2 | 10.5 |
Return on Assets | 7.2 | 8.0 | 3.2 | 4.8 | 2.5 |
Pre-tax ROIC | 10.8 | 14.1 | 7.8 | 8.5 | 7.0 |
Efficiency + | |||||
Days Payable | 131.0 | 112.0 | 122.0 | 114.0 | 112.0 |
Days Inventory | 124.0 | 133.0 | 183.0 | 184.0 | 210.0 |
Days Receivable | 164.0 | 128.0 | 122.0 | 107.0 | 120.0 |
Fixed Asset Turnover | 3.0 | 3.8 | 3.6 | 4.1 | 3.5 |
Total Asset Turnover | 0.7 | 0.9 | 0.8 | 0.9 | 0.8 |
Working Capital | |||||
Cash Conversion Cycle | 157.0 | 149.0 | 183.0 | 177.0 | 218.0 |
Working Capital Days | 132.0 | 124.0 | 132.0 | 131.0 | 137.0 |
IDBI Trusteeship Services Limited
No. of Loans: 1
Total Amount : 850.0 cr
IDBI Bank Limited
No. of Loans: 3
Total Amount : 96.6 cr
Mahindra and Mahindra Financial Services Limited
No. of Loans: 5
Total Amount : 6.1 cr
Bank of India
No. of Loans: 9
Total Amount : 0.9 cr
Name | State / Country | Incorporation Year | Paidup Capital |
---|---|---|---|
HETERO BIOTECH LIMITED | Telangana | 2004 | ₹ 5.0 L |
Read more
The incorporation date of HETERO DRUGS LIMITED is 06 April, 1993
The authorized share capital of HETERO DRUGS LIMITED is INR ₹ 10.0 Cr.
The paid-up capital of HETERO DRUGS LIMITED is INR ₹ 3.5 Cr.
The registered address of HETERO DRUGS LIMITED is #7-2-A2, INDUSTRIAL ESTATE, SANATHNAGAR, Sanathnagar I E, Hyderabad, Hyderabad, Telangana, India, 500018 - 500018
The CIN number of HETERO DRUGS LIMITED is U24230TG1993PLC015582.